How Incepta Is Shaping Bangladesh's Vaccines Future
Executive Summary
Bangladesh's Incepta group has launched its vaccine bulk manufacturing facility – a move that could have a significant impact on cost dynamics in a country that imports over 90 million doses of vaccines each year under its infant immunization plan. Incepta's chair Abdul Muktadir tells Scrip why this facility can make a difference and also outlines plans on the firm's tetravalent HPV vaccine.
You may also be interested in...
Hilleman Eyes Bangladesh Approval Of Novel, Cheaper Cholera Vaccine This Year
Indian vaccine research organization Hilleman Laboratories says it is hoping to get its "new design", cheaper cholera vaccine licensed in Bangladesh this year and that the next step will be to seek to make it available to UN agencies amid remaining global inoculation need.
Incepta’s Vaccine Ambitions Bridled By Bangladesh Regulatory Gap
Bangladesh's Incepta Vaccine is gearing up for a larger play with vaccines for pneumonia and human papillomavirus in the pipeline, but a non-functional national regulatory authority in the country could stymie its ambitions in terms of large-scale supplies of other products to Unicef, at least in the short-term.
India IPR Realities: Pharma, Legal Heads Discuss Winds Of Change, ‘Damocles Sword’
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.